Intelligence Profile
Clinical Applications
Recaticimab is used primarily for managing hypercholesterolemia and dyslipidemia. It is an Fc-engineered PCSK9 monoclonal antibody designed to provide a more prolonged lipid-lowering effect. Clinical applications of Recaticimab include:
Hypercholesterolemia: Recaticimab has shown efficacy in reducing LDL cholesterol levels in patients with hypercholesterolemia. A Phase 3 study (REMAIN-3) demonstrated its effectiveness in adult patients with heterozygous familial hypercholesterolemia, significantly lowering LDL cholesterol compared to placebo.
Dyslipidemia: Systematic reviews and meta-analyses confirm Recaticimab’s safety and efficacy in managing dyslipidemia, highlighting its favorable impact on lipid profiles and its long-lasting effects.
Acute Coronary Syndrome: Ongoing trials explore its impact on acute coronary syndrome (ACS), specifically assessing early intensive lipid-lowering therapy's effect on patient prognosis.
Potential in Atherosclerosis: While not yet recruiting, trials are planned to evaluate Recaticimab's role in treating intracranial atherosclerosis-related acute ischemic stroke and symptomatic stenosis, indicating potential broader cardiovascular applications.
Plasma Glucose Impact: Early-phase studies also suggest a potential impact on plasma glucose, although further research is needed.
In summary, Recaticimab is primarily used for lipid management in hypercholesterolemia and dyslipidemia, with ongoing research exploring broader cardiovascular benefits. Clinical trials continue to investigate its effectiveness in various contexts, including ACS and atherosclerosis.
Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice. Always consult healthcare professionals for medical concerns.